SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S33 - Progressive MS Therapeutics

Event Time: Wednesday April 26, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Daniel Ontaneda MD 


Speaker Disclosure
Daniel Ontaneda, MD Dr. Ontaneda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Biogen Idec.

Abstract Presenters

Start Time Pub. Title Presenter
3:54 PM 003 Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression Pablo Villoslada
Dr. Villoslada has received personal compensation for activities with Genzyme for participating in a scientific advisory board. Dr. Villoslada has received personal compensation in an editorial capacity for Current Treatment Options in Neurology. Dr. Villoslada holds stock and/or stock options in Bionure Inc. Dr. Villoslada has received research support from Biogen, Genzyme, Novartis and Merck Serono.

4:06 PM 004 Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab Michelle Mellion, MD
Compensation for consulting from Biogen, and Vertex. Research support from Annexon, Biogen, MedImmune, Novartis, Sanofi, and Teva.

4:18 PM 005 Development of a sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Peter Kosa, PhD
Dr. Kosa has nothing to disclose.

4:30 PM 006 The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study Deborah Miller, PhD
Dr. Miller has received personal compensation in an editorial capacity for Quality of Life Research. Dr. Miller has received research support from Novartis.

4:42 PM 007 Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Robert Fox, MD, FAAN
Consultant fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, and Teva... Research support from Biogen (clinical trial contracts) and Novartis (research study support).

4:54 PM 008 Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data Flavia Nelson
Dr. Nelson has received personal compensation for activities with Bayer, Sanofi-Genzyme, Genentech, Novartis, Teva, and CMSC. Dr. Nelson has received research support from National Institutes of Health, National MS Society, and Novartis.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN


Forgot Password?